Apogee Therapeutics APGE Stock
Apogee Therapeutics Price Chart
Apogee Therapeutics APGE Financial and Trading Overview
| Apogee Therapeutics stock price | 132.65 USD |
| Previous Close | 90.38 USD |
| Open | 132.55 USD |
| Bid | 95.48 USD x 200 |
| Ask | 169.76 USD x 200 |
| Day's Range | 132.5 - 133 USD |
| 52 Week Range | 34.34 - 133 USD |
| Volume | 61.22M USD |
| Avg. Volume | 974.52K USD |
| Market Cap | 9.99B USD |
| Beta (5Y Monthly) | 0.619 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.33 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 119.5 USD |
APGE Valuation Measures
| Enterprise Value | 5.72B USD |
| Trailing P/E | N/A |
| Forward P/E | -25.519783 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 7.8571424 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -18.844 |
Trading Information
Apogee Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.619 |
| 52-Week Change | 118.57% |
| S&P500 52-Week Change | 24.48% |
| 52 Week High | 133 USD |
| 52 Week Low | 34.34 USD |
| 50-Day Moving Average | 84.76 USD |
| 200-Day Moving Average | 69.38 USD |
APGE Share Statistics
| Avg. Volume (3 month) | 974.52K USD |
| Avg. Daily Volume (10-Days) | 1.11M USD |
| Shares Outstanding | 61.9M |
| Float | 57.83M |
| Short Ratio | 12.8 |
| % Held by Insiders | 9.64% |
| % Held by Institutions | 131.14% |
| Shares Short | 10.53M |
| Short % of Float | 22.00% |
| Short % of Shares Outstanding | 13.96% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -19.0049% |
| Return on Equity (ttm) | -28.47% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -303652000 USD |
| Net Income Avi to Common (ttm) | -274615008 USD |
| Diluted EPS (ttm) | -4.33 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.06B USD |
| Total Cash Per Share (mrq) | 14.14 USD |
| Total Debt (mrq) | 8.05M USD |
| Total Debt/Equity (mrq) | 0.64 USD |
| Current Ratio (mrq) | 32.587 |
| Book Value Per Share (mrq) | 16.87 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -234543008 USD |
| Levered Free Cash Flow (ttm) | -142579376 USD |
Profile of Apogee Therapeutics
| Country | United States |
| State | MA |
| City | Waltham |
| Address | Building 17 |
| ZIP | 02453 |
| Phone | 650 394 5230 |
| Website | https://www.apogeetherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 261 |
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Q&A For Apogee Therapeutics Stock
What is a current APGE stock price?
Apogee Therapeutics APGE stock price today per share is 132.65 USD.
How to purchase Apogee Therapeutics stock?
You can buy APGE shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Apogee Therapeutics?
The stock symbol or ticker of Apogee Therapeutics is APGE.
Which industry does the Apogee Therapeutics company belong to?
The Apogee Therapeutics industry is Biotechnology.
How many shares does Apogee Therapeutics have in circulation?
The max supply of Apogee Therapeutics shares is 75.18M.
What is Apogee Therapeutics Price to Earnings Ratio (PE Ratio)?
Apogee Therapeutics PE Ratio is now.
What was Apogee Therapeutics earnings per share over the trailing 12 months (TTM)?
Apogee Therapeutics EPS is -4.33 USD over the trailing 12 months.
Which sector does the Apogee Therapeutics company belong to?
The Apogee Therapeutics sector is Healthcare.
Apogee Therapeutics APGE included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25845.43 USD — |
-1.23
|
3.2B USD — | 25513.26 USD — | 25864.78 USD — | — - | 3.2B USD — |
- {{ link.label }} {{link}}